Sanofi has agreed to buy US biotech firm Inhibrx in a deal valued at up to $2.2bn, bolstering its drug development portfolio with an experimental treatment for a rare genetic disease. Under the terms of the agreement, Sanofi will acquire all outstanding shares of...

    Bora Pharmaceuticals, a contract development and manufacturing organization (CDMO), has officially acquired Upsher-Smith Laboratories, a specialty-brand and generics company, for $210 million. Upsher-Smith, founded in 1919 and owned by Sawai since 2017, has a...

    GSK’s acquisition, which comes amid other big money moves in the pharma industry, aims to broaden its asthma drug range. GSK’s acquisition will give the company access to Aiolos’ AIO-001, a monoclonal antibody that is ready to start Phase II trials for the treatment of...

  Zevra has obtained access to Acer’s rare disease assets Olpruva and Edsivo. Zevra Therapeutics has concluded its takeover of complete outstanding shares of Acer Therapeutics to form a rare disease company in a $91m deal. Zevra has obtained access to Acer’s rare...

    Alkermes plc, had announced that it has entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk, a leading global healthcare company. Under the terms of the agreement, upon the closing of the...

  Rain Oncology Inc, had announced that it has entered into a definitive merger agreement whereby Pathos AI, Inc. will acquire Rain Oncology. Privately held Pathos AI, a company focused on leveraging machine learning and real-world data in drug development, will make a cash...

Bristol Myers Squibb had announced a definitive merger agreement under that it will acquire RayzeBio for $62.50 per share in cash, for a total equity value of approximately $4.1 billion, or $3.6 billion net of estimated cash acquired. The transaction was unanimously approved by both...

Ajinomoto has signed a definitive agreement for the acquisition of contract development and manufacturing organisation and clinical-stage therapeutics company Forge Biologics in an all-cash transaction totalling $620m. The prospective takeover is part of Ajinomoto’s strategy to...

Bristol Myers Squibb (BMS) has signed a definitive agreement for the acquisition of all of outstanding shares of Mirati Therapeutics in a $5.8bn deal. The company plans to buy Mirati for $58 for each share in cash, representing an equity value of $4.8bn. Mirati shareholders will also...

Eli Lilly and Company has signed a definitive agreement for the acquisition of all outstanding shares of radiopharmaceutical company POINT Biopharma for an all-in cash price of $1.4bn. Lilly offered $12.5 for each share of POINT. POINT’s pipeline comprises radioligand cancer...